



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Marie-Paule Kieny et al.

Application No.: 09/462,993

Filing Date: April 17, 2000

Title: ANTITUMORAL COMPOSITION BASED ON IMMUNOGENIC POLYPEPTIDE WITH MODIFIED CELL LOCATION

Group Art Unit: 1632

Examiner:

Confirmation No.: 5746

AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a reply for the above-identified patent application.

☐ A Petition for Extension of Time is also enclosed.

☐ Terminal Disclaimer(s) and the ☐ \$55.00 (2814) ☐ \$110.00 (1814) fee per Disclaimer due under 37 C.F.R. § 1.20(d) are also enclosed.

☐ Also enclosed is/are \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

☐ Small entity status is hereby claimed.

☐ Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$385.00 (2801) ☐ \$770.00 (1801) fee due under 37 C.F.R. § 1.17(e).

☐ Applicant(s) requests that any previously unentered after final amendments not be entered. Continued examination is requested based on the enclosed documents identified above.

☐ Applicant(s) previously submitted \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_ on \_\_\_\_\_  
for which continued examination is requested.

☐ Applicant(s) requests suspension of action by the Office until at least \_\_\_\_\_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.

☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.

- ☐ No additional claim fee is required.
- ☒ An additional claim fee is required, and is calculated as shown below.

| AMENDED CLAIMS   |                  |  |              |                    |                 |
|--|------------------|--|--------------|--------------------|-----------------|
|  | No.<br>of Claims | Highest No.<br>of Claims<br>Previously<br>Paid For | Extra Claims | Rate               | Additional Fee  |
| Total Claims   | 34               | MINUS 42 =   | 0            | x \$18.00 (1202) = | \$ 0.00         |
| Independent Claims   | 5                | MINUS 4 =  | 1            | x \$86.00 (1201) = | \$ 86.00        |
| If Amendment adds multiple dependent claims, add \$290.00 (1203)                                 |                  |  |              |                    |                 |
| Total Claim Amendment Fee  |                  |  |              |                    | \$ 86.00        |
| <input type="checkbox"/> Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee |                  |  |              |                    | \$ 0.00         |
| <b>TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT</b>   |                  |  |              |                    | <b>\$ 86.00</b> |

- ☒ A check in the amount of \$ 86.00 is enclosed for the fee due.
- ☐ Charge \_\_\_\_\_ to Deposit Account No. 02-4800.
- ☐ Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.


P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: August 17, 2004

By



Christopher L. North, Ph.D.  
Registration No. 50,433



Patent 1632  
Attorney's Docket No. 017753-122 JFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

Marie-Paule Kieny et al.

Application No.: 09/462,993

Filed: April 17, 2000

For: ANTITUMORAL COMPOSITION  
BASED ON IMMUNOGENIC  
POLYPEPTIDE WITH MODIFIED  
CELL LOCATION

) **Mail Stop: Amendment**

) Group Art Unit: 1632

) Examiner: Qian Janice Li

) Confirmation No.: 5746

**AMENDMENT & REPLY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated May 17, 2004, please amend the above-  
identified patent application as follows:

08/18/2004 GWORDOF1 00000077 09462993

01 FC:1201

86.00 0P